Pulmonary tuberculosis: Focus on the fluoroquinolones

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 341-352

  Goldberg, Stefan ^a   LoBue, Philip ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug resistant; Fluoroquinolones; Treatment; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; GREPAFLOXACIN; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; RIFAMPICIN; RIFAMYCIN; STREPTOMYCIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ACHILLES TENDON RUPTURE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL RESEARCH; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGLYCEMIA; EXPOSURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INFECTION CONTROL; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; METABOLIC DISORDER; MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PHOTOSENSITIVITY; QT PROLONGATION; RASH; REVIEW; SEIZURE; SKIN DISEASE; TENDINITIS; TREATMENT DURATION; VOMITING;

EID: 77952691796     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s1974     Document Type: Review

References (92)

1. Daniel TM. The impact of tuberculosis on civilization. Infect Dis Clin N Am. 2004;18:157-65.
2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231-79.
3. World Health Organization. Global tuberculosis control-epidemiology, strategy, financing. 2009. http://www.who.int/tb/publications/global_report/2009/en/index.html
4. CDC. Reported Tuberculosis in the United States, 2008. Atlanta, GA: U.S. Department of Health and Human Services, CDC, September 2009.
5. American Thoracic Society and the Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376-95.
6. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62.
7. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Am J Respir Crit Care Med. 2001;162:1055-8.
8. Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009;30:755-68.
9. Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridine antibacterial agents. Chem Rev. 2005;105:559-92.
10. Tsukamura M, Nakamura E, Yoshii S, Amano H. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis. 1985;131:348-51.
11. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47:653-7.
12. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985;131:352-6.
13. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849-62.
14. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2009 Jan 23;(1):CD004795.
15. Maxwell A. DNA gyrase as a drug target. Trends Microbiol. 1997; 5(3):102-9.
16. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis. 1998;2(4):265-71.
17. Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V, Sriram D. Antimycobacterial activities of novel fluoroquinolones. Biomedicine and Pharmacotherapy. 2009;63:27-35.
18. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(Suppl 2):29-36.
19. O'Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin North Am. 2004;18:691-716.
20. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy. 2000;20:245-56.
21. O'Donnell JA, Gelone SP. Fluoroquinolones. Infect Dis Clin North Am. 2000;14:489-513.
22. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother. 2007;51: 2861-6.
23. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45:1001-7.
24. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3:432-42.
25. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis. 2008; 88(Suppl 1):S65-74.
26. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51:576-82.
27. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis. 2004;23:243-55.
28. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852-7.
29. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000;44:2600-3.
30. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99.
31. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352-61.
32. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect-Dis. 2009;49(3):402-8.
33. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest. 2005;128:1406-13.
34. Ho CC, Chen YC, Hu FC, Yu, CJ, Yang, PC, Luh KT. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 2009;48:1526-33.
35. Chang KC, Leung CC, Yew WW, et al. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients. Int J Tuberc Lung Dis. 2009;13(3):341-6.
36. Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, CA: Francis J. Curry National Tuberculosis Center; 2008. http://www.nationaltbcenter.ucsf.edu/drtb/index.cfm
37. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2008. WHO/HTM TB/2008.402.
38. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169:1103-9.
39. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA. 1996;276:1229-35.
40. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multi-drug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006; 28:980-5.
41. Yew WW, Chan CK, Chau, CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117:744-51.
42. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318-26.
43. Tahaoǧlu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170-4.
44. Miglori GB, Lange C, Girardi E, et al; and the SMIRA/TBNET Study Group. Fluroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J. 2008;31:904-5.
45. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180(4): 365-70.
46. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother. 2009;53:4498-500.
47. Lounis N, et al. Which aminoglycoside or fluoroquinolone is more active against mycobacterium tuberculosis in mice? Antimicrobial Agents and Chemotherapy. 1997;41(3):607-10.
48. Dong Y, et al. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrobial Agents and Chemotherapy. 1998;42(11):2978-84.
49. Zhao BY, et al. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrobial Agents and Chemotherapy. 1999;43(3):661-6.
50. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res. 1995;21:79-83.
51. Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res. 1992;12:173-8.
52. Bergstermann H, Rüchardt A. Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis. Infection. 1997;25:227-32.
53. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1-51.
54. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR. 1992;41(No. RR-11):59-71.
55. Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy. 2002;22:701-4.
56. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002;167:131-6.
57. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis. 1997;24:1264-5.
58. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003; 37:1448-52.
59. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother. 2005;56:1058-62.
60. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis. 2009;48:1354-60.
61. Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis. 2009;48(10):1354-60.
62. Bernardo J, Yew WW. How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir Crit Care Med. 2009;180:280-9.
63. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34:1607-12.
64. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903-8.
65. Chang KC, Leung CC, Yew WW, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J. 2009 Aug 28 [Epub ahead of print].
66. von Gottberg A, Klugman KP, Cohen C, et al; for the Group for Enteric Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet. 2008;371:1108-13.
67. Reichman LB. Tuberculosis drug resistance comes full circle. Lancet. 2008;371:1052-3.
68. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999;44(3):393-5.
69. Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoro-quinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2001;17(3):229-31.
70. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42(8):2066-9.
71. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother. 1999;43(1):85-9.
72. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 2001;45(12): 3482-6.
73. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 2002;46(6):1875-9.
74. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 1993;147:1062-3.
75. Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009;9:162-72.
76. Nunn AJ, Phillips PPJ, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis. 2010;14(2):241-2.
77. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972:1079-85.
78. East African/British Medical Research Council. Controlled trial of four short-course (6-month) regimens of chemotherapy for the treatment of pulmonary tuberculosis. Lancet. 1974;2:1100-6.
79. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis. 1978;118:39-48.
80. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Am Rev Respir Dis. 1978;118:219-27.
81. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 1981;1:171-4.
82. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb). 2008;88:S85-92.
83. Tuberculosis Research Centre, Chennai. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc. 2002;49:27-38.
84. Neurmberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-6.
85. Burman WJ, Goldberg S, Johnson JL, et al. Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:331-8.
86. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial. Lancet. 2009;373:1183-9.
87. Rustomjee R, Lienhardt C, Kanyok T, et al; Gatifloxacin for TB (OFLO-TUB) study team. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12(2):128-38.
88. Dorman SE, Johnson JL, Goldberg S, et al; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180:273-380.
89. Mitchison DA, Chang KC. Experimental models of tuberculosis: can we trust the mouse? Am J Respir Crit Care Med. 2009;180:201-2.
90. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44: S27-72.
91. WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world: report no 4. Geneva: WHO 2008.
92. Global Alliance for Tuberculosis Drug Development. Tuberculosis scientific blueprint for TB drug development. Tuberculosis (Edinb). 2001; 81(Supp1):1-52.